AxoGen, Inc. to Host Panel on Nerve Repair at the American College of Oral and Maxillofacial Surgeons 2013 Annual Meeting

Physician Education Event Highlights New Treatment Options for Trigeminal Nerve Repair.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

AxoGen Logo

"Avance® Nerve Graft now allows us the opportunity to offer patients an option for nerve repair with processed human nerve allograft,” Michael Miloro, DMD, MD, FACS, Professor & Chair of OMFS, University of Illinois

Alachua, FL (PRWEB) April 16, 2013

AxoGen, Inc. (OTCBB: AXGN) a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it is sponsoring a panel discussion on nerve repair and protection at the American College of Oral and Maxillofacial Surgeons (ACOMS) 2013 Annual Scientific Conference and Exhibition. AxoGen will also be featuring its innovative nerve regeneration platform at the conference, which is being held April 20-22, 2013 in Scottsdale, AZ.

The panel, which is titled “Contemporary Approaches to Nerve Protection and Repair,” will be held on Sunday, April 21, 2013 from 3:30-5:00 pm PT. Presentations will include an overview of the science of nerve repair and case studies utilizing AxoGen’s Avance® Nerve Graft, AxoGuard® Nerve Protector, and AxoGuard® Nerve Connector to repair damage to the trigeminal nerve. The trigeminal nerve is the largest of the cranial nerves and is responsible for sensation in the mouth and taste. A common cause of damage to the trigeminal nerve is the extraction of third molars (wisdom teeth).

The panel will be moderated by Michael Miloro, DMD, MD, FACS, Professor and Chair of OMFS, University of Illinois. The panelists will include Shahrokh Bagheri, DMD, MD, FACS, Chief of OMFS, Northside Hospital; John Zuniga, DMD, PhD, Professor and Chair of OMFS, University of Texas Southwestern Medical Center; and Erick DeVinney, Director of Clinical and Translational Sciences, AxoGen.

Dr. Miloro said, “At the University of Illinois in Chicago, we frequently see patients with damage to the terminal branches of the trigeminal nerve, most commonly as a result of dental and oral surgery procedures, such as the removal of impacted wisdom teeth. Avance® Nerve Graft now allows us the opportunity to offer these patients an option for nerve repair with processed human nerve allograft, avoiding the donor site morbidity of autogenous nerve grafting, when indicated.”

Jill Schiaparelli, Senior Vice President, Business Strategy & Marketing, of AxoGen, said, “The ACOMS Panel provides an excellent forum for surgeons to discuss common clinical challenges when treating oral nerve damage and highlight their experiences with AxoGen’s nerve regeneration solutions. Due to the prevalence of this type of injury following common dental procedures like wisdom teeth removal and dental implants, we believe there is a strong need for innovative nerve regeneration options, and feel this market represents a solid growth opportunity for AxoGen and our technology platform.”

For more information on AxoGen and its technology, please visit http://www.axogeninc.com.

About AxoGen, Inc.
AxoGen (AXGN) is a regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. For more information, visit our website at http://www.axogeninc.com.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL. To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.


Contact